LncRNA PITPNA-AS1 mediates the diagnostic potential of miR-129-5p in prostate cancer

Background LncRNA has an effective value in many diseases, which has long been applied in the diagnosis, treatment and prognosis of prostate cancer.

This study focused on lncRNA PITPNA-AS1, and its diagnostic potential in prostate cancer has been explored.

Methods The expression of PITPNA-AS1 and miR-129-5p in prostate cancer serum and sample cells was determined by real-time quantitative polymerase chain reaction (RT-qPCR).

The relationship between the expression of PITPNA-AS1 and clinicopathological parameters was considered.

ROC curve prompted the diagnostic value of PITPNA-AS1.

The effect of PITPNA-AS1 on prostate cancer cells was verified using vitro cells assay.

Luciferase activity assay and RIP assay demonstrated the sponge relationship of PITPNA-AS1 to miR-129-5p.

Results PITPNA-AS1 level was increased, while miR-129-5p was obviously decreased in prostate cancer.

PITPNA-AS1 expression was associated with Gleason grade, lymph node metastasis and TNM stage in patients.

The area under the curve (AUC) was 0.910, with high sensitivity and specificity.

PITPNA-AS1 was elucidated to directly target miR-129-5p, whereas silencing PITPNA-AS1 negatively affected prostate cancer cell proliferation, migration and invasion.

Intervention of miR-129-5p inhibitor reversed the effect of silencing PITPNA-AS1 on cells.

Conclusions PITPNA-AS1 was relatively highly expressed in prostate cancer and mediated the pathophysiological process of patients, which may serve as a diagnostic indicator.

Silencing of the PITPNA-AS1 sponge miR-129-5p inhibited the biological function of the cells, indicating that PITPNA-AS1 may represent a novel therapeutic target for prostate cancer.